A drug that scientists are calling “cancer’s equivalent of breaking the four-minute mile” is nearing regulatory approval. Daraxonrasib targets a protein that drives nearly all pancreatic tumors — as well as many lung and colon cancers — and in a late-stage pivotal trial, it nearly doubled median survival in patients with metastatic pancreatic cancer from 6.7 months to 13.2 months.

The innovation is striking for its potential to reinvent treatment approaches and is being compared to immunotherapy’s breakthrough impact 15 years ago.

It’s also notable for where it falls in a broader pattern: While breakthroughs like Daraxonrasib come sporadically, medical knowledge overall is advancing at a pace that no individual clinician, health system, or country can fully absorb on its own—and with global, multidisciplinary medical second opinions more accessible than ever through health plans, critical illness insurance, and even services like credit card or hotel affinity perks, they don’t have to.  

Oncology’s Pace of Innovation is A Wake-Up Call for Health Plans

Drug and medical technology advancements provide tangible metrics for the staggering pace of medical innovation. Consider what has happened in recent months alone:

• • As of May 2026, the European Medicines Agency had issued 36 positive opinions on new medicines and 59 additional opinions extending the approved uses of existing treatments.

• • Health Canada authorized 56 new pharmaceutical drugs, 23 new biologic drugs, 134 generic pharmaceutical drugs, and 12 biosimilars between April 2025 and February 2026. Of those, 43 contain medicinal ingredients never previously approved for sale in Canada.

• • As of June 1, 2026, the U.S. Food and Drug Administration has approved 20 brand-new drugs, not counting new indications.

The pace of oncology innovation, in particular, continues to accelerate. In the last decade, 115 cancer treatments were newly approved for the top 10 most prevalent cancer types — up from 28 approvals in the decade before, according to an Airfinity analysis that also notes a significant portion are combination treatments used in targeted therapies.

Multidisciplinary Medical Second Opinions Help Insurers Close the Knowledge Gap

Medical knowledge is now estimated to double every 73 days, according to the American Society of Clinical Oncology. No single physician can keep pace with that. As surgeon and author Atul Gawande has argued, medicine has grown too complex for the solo expert model. The modern standard requires multidisciplinary, team-based specialist care.

This is where global medical second opinions become critical. When a patient in Poland, Canada or Saudi Arabia receives a serious diagnosis, their outcome depends on whether their care team has access to the specialists who know the latest evidence and can apply it to their specific case.

A breakthrough nearing FDA or EMA approval today may be the standard of care within a year. For group health plans, critical illness policies, and TPAs serving members across North America, Europe, Africa and the Gulf, an international expert medical opinion service is no longer a supplemental offering — it is a benefit enhancement that directly affects the quality of care members receive and the accuracy of the claims that follow.

Offering access to multidisciplinary team second opinions on serious and complex diagnoses is one of the clearest forms of group benefits innovation available to insurers today. In a market where medical knowledge is compounding faster than any one physician can track, it is also one of the most defensible.